Wide pH variations or high temperatures are tough conditions for a silica based HPLC column. Kromasil Eternity, with its organic/inorganic interfacial gradient on the matrix, can longer withstand such conditions.
Based on the ever increasing demand on HPLC-, and UHPLC-columns, Kromasil Eternity is developed on a new generation of porous Kromasil silica particles, 2.5 and 5.0 µm. The technology implemented leads to the formation of an organo-silica particle. The organic/inorganic interfacial gradient towards its surface ensures a long lifetime for this analytical silica matrix under a wide pH range: 2 – 12. Subsequent functionalization and end-capping of the organo-silica particle is performed using well known chlorosilane based chemistry, providing a material suited for most demanding separations.
The Eternity platform is, at the moment, available as Eternity C18 and PhenylHexyl. Eternity C18 is a long lasting product even under tough pH conditions as well as at high temperatures. Eternity PhenylHexyl provides you with an alternative selectivity compared to a traditional alkyl chain phase or a polar embedded phase, especially with aromatic analytes.
Visit our website for more information about Kromasil Eternity:
ref="http://www.kromasil.com/LCGCen1211">www.kromasil.com/eternity
Email:
ref="mailto:kromasil@akzonobel.com">kromasil@akzonobel.com
HPLC 2025 Preview: Fundamentally Speaking (Part 1)
May 13th 2025Michael Lämmerhofer from the Institute of Pharmaceutical Sciences, University of Tübingen, Germany, spoke to JFK Huber Lecture Award winner of 2024 Torgny Fornstedt, professor in analytical chemistry and leader of the Fundamental Separation Science Group, Karlstad University, Sweden, about his pioneering work in high performance liquid chromatography (HPLC) with a focus on fundamentals and industrial applications.
Biopharmaceutical Characterization in the Age of Artificial Intelligence
May 13th 2025AI-powered tools are enhancing precision, efficiency, and decision-making in biopharmaceutical development. Recently, Jared Auclair and Anurag Rathore explored AI's evolving role in biopharmaceuticals in detail.